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The role of γδT cells in immunotherapy has gained specific importance in the recent years
because of their prominent function involving directly or indirectly in the rehabilitation of
the diseases. γδT cells represent a minor population ofT cells that express a distinctT cell
receptor (TCR) composed of γδ chains instead of αβ chains. Unlike αβ T cells, γδ T cells
display a restricted TCR repertoire and recognize mostly unknown non-peptide antigens.
γδ T cells act as a link between innate and adaptive immunity, because they lack pre-
cise major histocompatibility complex (MHC) restriction and seize the ability to recognize
ligands that are generated during affliction. Skin epidermal γδ T cells recognize antigen
expressed by damaged or stressed keratinocytes and play an indispensable role in tis-
sue homeostasis and repair through secretion of distinct growth factors. γδ T cell based
immunotherapy strategies possess great prominence in the treatment because of the
property of their MHC-independent cytotoxicity, copious amount of cytokine release, and
a immediate response in infections. Understanding the role of γδ T cells in pathogenic
infections, wound healing, autoimmune diseases, and cancer might provide knowledge
for the successful treatment of these diseases using γδ T cell based immunotherapy.
Enhancing the human Vγ9Vδ2 T cells functions by administration of aminobisphospho-
nates like zoledronate, pamidronate, and bromohydrin pyrophosphate along with cytokines
and monoclonal antibodies shows a hopeful approach for treatment of tumors and infec-
tions. The current review summarizes the role of γδT cells in various human diseases and
immunotherapeutic approaches using γδT cells.
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INTRODUCTION
T cells are the principal lymphocytes that play a vital role in cell-
mediated immune responses. Majority of the T cells are αβ T cells
with α and β chains and a minor population of γδ T cells do
exist that play a pivotal role in the host defense system (1). γδ T
cells are located in peripheral blood (PB), intestine, skin, spleen,
and lymph nodes where they were found to act as interface for
the cross talk between innate and cell-mediated immune cells (2).
The functional development of γδ T cells is initiated much ear-
lier than the development of αβ T cells in embryogenesis, where
γδ T cell Receptor (TCR) gene rearrangements were detected in
the fetal thymus by “day 14” of embryogenesis (E14). The earli-
est murine γδ T cell “wave” expresses Vγ3Vδ1 and gives rise to
skin dendritic epidermal γδ T cells (DETC). Later, vaginal and gut
intra-epithelial γδ T lymphocytes (IEL) and immune organ γδ T
cells were developed (3). Vγ3Vδ1 DETCs are exclusively generated
in the fetal thymus, migrate to epidermal epithelia, expand locally
and are maintained throughout the life of an individual (4). γδ T
cells express TCR molecule on their cell surface, but there are only
a few variable genes available to construct Vγ/Vδ TCR proteins. In
addition, the usage of the Vγ/Vδ genes is not random but appears
to be dictated by the localization of γδ T cells (5). Hence γδ T cells
are well engaged in newborns to contribute to immune-protection
and immune-regulation (6, 7).
γδ TCR recognize non-peptide antigens like glycerolipids and
other small molecules, polypeptides that are soluble or mem-
brane anchored, and cross linked to major histocompatibil-
ity complex (MHC) molecules or MHC-like molecules in an
antigen-independent manner (8). Human Vγ9Vδ2 (also known as
Vγ2Vδ2) T cells can be activated by metabolites from isoprenoid
synthetic pathway. These include (E)-4-hydroxy-3-methyl-but-2-
enyl pyrophosphate (HMBPP), exogenous prenyl pyrophosphate
from bacteria and parasitic protozoa and isopentenyl pyrophos-
phate (IPP), and endogenous prenyl pyrophosphate deriving from
mevalonate pathway that operates in human. Aminobisphospho-
nates may activate Vγ9Vδ2 T cells by inhibiting the key enzyme
farnesyl pyrophosphate synthase of mevalonate pathway in cer-
tain tumors leads to upregulating the endogenous pool of IPP
(9). Vavassori et al. identified butyrophilin BTN3A1 molecule,
which is involved in the presentation of phosphorylated antigens to
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Vγ9Vδ2 T cells (10). Recently, Sandstrom et al. demonstrated that
intracellular B30.2 domain of butyrophilin 3A1 (BTN3 A1) pro-
tein binds phosphoantigens (pAg) to mediate activation of human
Vγ9Vδ2 T cells. This intracellular B30.2 domain of BTN3A1
directly binds pAg through a positively charged surface pocket
and charge reversal of pocket residues abrogates binding and
activation of Vγ9Vδ2 T cells (11). Furthermore, Uldrich et al.
reported that CD1d presents lipid-based antigens to human Vδ1+
γδ T cells (12). γδ T cells use both the TCR and also addi-
tional activating receptors like natural killer (NK) cell activating
receptor (NKG2D), toll like receptor (TLR), and NOTCH sig-
naling to respond to stress induced ligands and infection (13).
Activated γδ T cells promote the anti-infection capabilities of res-
ident macrophages, NK cells, and also enhance the maturation
of dendritic cells (DCs). Besides that, they secrete cytokines and
chemokines to recruit pro-inflammatory neutrophils to accelerate
the elimination of pathogens and the repair of damaged tissues.
Neutrophils in turn suppress the γδ T cells activation to reduce
the inflammation when the infection has been resolved (14). In
addition, γδ T cells in the skin produce keratinocyte growth fac-
tor (KGF), important cytokine for wound repair, and epithelial
cell regeneration. It has been demonstrated that the human γδ
T cells activation and expansion can be controlled by forkhead
box P3 (FOXP3) expressing regulatory T cells (Tregs), programed
death-1 (PD-1), and cytotoxic T lymphocyte antigen (CTLA)-4
both in vivo and in vitro (15).
γδ T cells bridge innate and adaptive immunity and play a pro-
tective role in immune-surveillance. Effector γδ T cells produce
interferon (IFN)-γ, tumor necrosis factor (TNF)-α,which enhance
cell-mediated immune response and interleukin (IL)-17 that plays
a vital role in early neutrophil mediated response. In addition,
cytotoxic components such as perforin, granzymes secreted by
these cells ultimately cause direct or indirect effect of cytotoxicity
against infected cells (16). They provide a wide range of defense
mechanisms against microorganisms such as viruses,bacteria,pro-
tozoa, and diseases like cancer and also in healing of wounds and
burns. In addition, γδ T cells also play a role in autoimmune dis-
eases such as rheumatoid arthritis (RA) and systemic lupus erythe-
matosus (SLE) through their antigen-presenting capacity, release
of pro-inflammatory cytokines, immunomodulatory properties,
interaction with Tregs, and promotion of antibody production
(17). Pantelyushin et al. reported that apart from retinoid-related
orphan receptor gamma-t (RORγt+) innate lymphocytes, γδ T
cells also produce cytokines like IL-17A, IL-17F, and IL-22 that are
essential and enough for psoriatic plaque formation in a disease
model that closely resembles human psoriatic plaque formation
(18). Current review exclusively focuses on the role γδ T cells
in specific pathogenic infections, anti-tumor activity, healing of
wounds and burns, autoimmune diseases, and few insights on
their immunotherapy.
PATHOGENIC INFECTIONS
TUBERCULOSIS
Tuberculosis caused by Mycobacterium tuberculosis (Mtb) is con-
sidered to be one of the serious infectious disease worldwide
causing 1.7 million deaths every year. Around 30% of the world’s
population is affected by M. tuberculosis and approximately 100
million people died due to tuberculosis (TB) over the last century
(19). Hence, there is an urgent need to find out the host factors
that delineate the individuals susceptible to TB. pAg such IPP and
HMBPP are the key ligands that activateVγ9Vδ2 T cells. HMBPP is
nearly 1000-fold more effective than IPP for the in vitro activation
of Vγ9Vδ2 T cells (20). Mtb produces HMBPP, which is recog-
nized by Vγ9Vδ2 TCR and drives the activation of Vγ9Vδ2 T cells
(21). Effector Vγ9Vδ2 T cells are shown to participate in the anti-
TB immune response by production of various cytokines (Th1,
Th2, and Th17) and also activation of other immune cells such
as CD4+ and CD8+ T cells, B cells, DCs, and macrophages (22).
The in vivo studies have demonstrated that the major expansion of
Vγ9Vδ2 T cells in macaques is induced only by HMBPP plus IL-2
co-treatment, but not IL-2 or HMBPP alone (23) although IL-
2 treatment of macaques expands CD4+CD25+Foxp3+Treg cells
(24). In a primate model for TB, γδ T cells produce IL-22 ini-
tially, which can be down regulated by HMBPP. There are various
subsets of γδ T cells, which are self regulative, and HMBPP treat-
ment during early stages of infection might be helpful in evading
Mtb (25). Peng et al. showed that upon stimulation with Mtb heat
treated antigen (Mtb-HAg), levels of IFN-γ producing Vγ9Vδ2
T cells increased in number and were the main source of IL-17
(26). This led to the increased recruitment of phagocytic cells
to the infected site and formation of granulomas in pulmonary
TB. This reaction was antigen specific, because immunizing the
same host once again with Mtb-HAg has led to faster reactiva-
tion of Vγ9Vδ2T cells. Thus, stimulation of Vγ9Vδ2 T cells with
pyrophosphates like IPP and HMBPP might represent a novel
vaccine strategy to identify the key effector pathways of Mycobac-
teria stimulated Vγ9Vδ2 T cells that potentially act to inhibit the
intracellular growth of Mycobacteria. In addition to that, human
Vγ9Vδ2 T cells can recognizes many pathogen antigens and show
rapid immune responses during infections including E. coli infec-
tions, salmonellosis, brucellosis, leprosy, tularemia, legionellosis,
and listeriosis (27).
Bovine TB is caused by Mycobacterium bovis is a major zoonotic
problem in United Kingdom and developing countries. γδ T cells
show a major immunological response against M. bovis infec-
tion. Workshop cluster 1 (WC1) molecule expressed on Vγ9Vδ2
T cells is involved in the antigen recognition including heat-
shock proteins, phospholipids derived from Mycobacteria, and
other non-peptide antigens. WC1+ γδ T cells are important in the
development of granulomas during M. bovis infection by upregu-
lating IFN-γ, IL-12, IL-18, MHC II, CD80/86, CD40, and adhesion
molecules (22).
MALARIA
Malaria is a mosquito borne infectious disease caused by parasitic
protozoan Plasmodium falciparum in humans and other animals.
The WHO report 2013, has an estimate of 207 million cases of
malaria with approximately 0.627 million deaths and 3.4 billion
people prone to the risk of malaria (28). The information about
the in vivo activation and anti-plasmodial action of the Vγ9Vδ2
T cells is indistinct and it is important to understand the mecha-
nisms of early control of the parasite multiplication and parasite
density. It has been shown that elevated levels of γδ T cells in PB
and spleen occur during acute plasmodium infection (29). γδ T
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cell-deficient [TCRδ-knockout (KO)] mice were unable to clear
the infected red blood cells, showed high parasitemia and eventu-
ally died (30). Therefore, γδ T cells have the potential to react with
malaria antigens rather than the αβ T cells or by NK cells (31).
Vγ9Vδ2 TCR recognizes schizont associated antigen (SAA) and
HMBPP, are the antigens of P. falciparum result in the activation of
Vγ9Vδ2 T cells (31, 32). Activated γδ T cells produce huge amount
of IFN-γ in presence of activated monocyte cytokines IL-10, IL-2,
and IL-1β. TLR-sensitized DCs express enhanced co-stimulatory
factors on their surface and induce high levels of IFN-γ produc-
tion by human Vγ9Vδ2 T cells (33). The CD40 ligand on γδ T
cells is ligated with CD40 on DCs and this signaling synergistically
enhances the uptake of plasmodium antigens via DCs by increas-
ing the production of IL-12 (30). Previous reports suggest that
the number of polyclonally activated Vδ2+ T cells increase in PB
during the acute phase of P. falciparum in malaria. In addition,
in vitro activated Vγ9Vδ2 T cells express granzyme-A and B, per-
forin, Fas/Fas ligand (FasL) and granulysin to kill the asexual stages
of P. falciparum in the blood as well as inhibit the growth of intra
erythrocytic stages (34). The P.falciparum was also known to be
inhibited by human Vγ9Vδ2 T cells in vitro. The targets recognized
by Vγ9Vδ2 T cells are extracellular merozoites of the host erythro-
cytes and this exclusively requires the contact between γδ T cells
and the merozoites (35). Both the blood stages of intra erythro-
cytic parasite and extracellular merozoites themselves activates the
Vγ9Vδ2 T cells resulting in their degranulation by granulysin, but
not by perforin (36). Teirlinck et al. reported that Vγ9Vδ2 T cells
have the ability to develop effector memory cells after infection
with P. falciparum (37) and this feature might be helpful in the
development of novel cell based malaria vaccine.
ACQUIRED IMMUNODEFICIENCY SYNDROME
Acquired immunodeficiency syndrome is caused by human
immunodeficiency virus (HIV) and is one of the greatest health
crises ever faced by the global community. It has been demon-
strated that circulating Vγ9Vδ2 T cells exhibit anti-HIV role
by secreting chemokines for HIV entry co-receptors, producing
soluble antiviral factors, and killing the infected cells by the mech-
anisms similar to cytotoxic T lymphocytes (CTL) and NK cells.
However, Vγ9Vδ2 T cells are found to be depleted in the advanced
stages of the HIV infection and the insufficient number of Vγ9Vδ2
T cells leads to increased potential for chronic inflammation. The
envelope glycoprotein 120 (gp120) of CCR5 tropic strains of HIV
could bind with the surface receptors CCR5 and α4β7 expressing
on γδ T cells. This binding activates the P38 MAP kinase, which in
turn promotes the Fas dependent caspase activation and induces
the cell death (38). Further, when macaques were immunized with
proteins like simian immunodeficiency virus (SIV) gp120 and gag
p27 induced the production of chemokines CCL-3, CCL-4, CCL-5
(RANTES), which in turn bind with the CCR5 thus inhibiting the
entry of HIV into the host (39). The levels of these chemokines
were increased by the engagement of the ectopically expressed
receptors called Natural Cytotoxic Receptors (NCRs) like NKP30
on the surface of the Vδ1 T cells that induced the production
of high levels of significant chemokines and controlled the lev-
els of HIV (40). However, activated Vγ9Vδ2 T cells may directly
suppress HIV replication by releasing CC-chemokines, competing
with HIV for CCR5 entry coreceptor, and other soluble antiviral
factors (41). Hence, the treatment approaches might include tar-
geting proviral infection using the activation of Vγ9Vδ2 T cells
with aminobisphosphonates and IL-2 to improve the anti-viral
activity but not on the prolonged virus as the viral load is severe
in this condition. γδ T cells coordinate activated innate immu-
nity with adaptive antibody and T cell responses in preventive
vaccination against HIV-1 infection.
Apart from HIV, γδ T cells were known to be involved in
following viral infections. γδ T cells are highly specific to the
micro-environment in which they thrive and said to possess organ
specific functions. γδ T cells in liver produce IL-17 is very essential
for meliorating adenovirus mediated hepatitis, neutralizing IL-17
with antibodies aggravated these conditions (42). γδ T cells can
compensate neutrophil IL-17 production. For instance, when mice
were infected with Cryptococcus neoformans strain-H99γ, which
leads to neutropenia, IL-17 producing γδ T cells mediated the reg-
ulation of innate and adaptive cells to mount a successful immune
response (43). γδ T cells were known to possess memory just like
other adaptive immune cells. This character of γδ T cells was
brought into limelight by the association of γδ T cells response
on cytomegalovirus (44). γδ T cells were reduced in number dur-
ing sepsis and acute reduction of these cells resulted in mortality
of patients suffering with sepsis (45). The protective role of γδ
T cells have also been confirmed in few other infectious diseases
caused by viruses including influenza virus,West Nile virus, herpes
simplex virus, Epstein–Barr virus, and human hepatitis virus C.
CANCER
γδ T cells have a unique role in the immune-surveillance against
malignancies and also an advantage over αβ T cells because they
can directly recognize molecules that are expressed on cancer cells
without need of antigen processing and presentation (46). An
important therapeutic feature of γδ T cells is that these favorably
kill cancer cells and show low reactivity toward non-transformed
cells (47). Variable region of the Vγ9Vδ2 TCR plays a major
role in recognition of the antigen (48). Vγ9Vδ2 TCR recognize
increased pool of endogenous IPP, which may only be found in
tumor cells but not in healthy tissues. Activated Vγ9Vδ2 TCRs
promote γδ T cell cytotoxicity through increased secretion of per-
forin/granzymes, IFN-γ, and TNF-α, IL-17, up-regulates expres-
sion of FasL and TNF-related apoptosis-inducing ligand (TRAIL)
(49). Among the list of mediators promoting anti-cancer cytotoxi-
city mentioned above, IL-17 in tumor micro-environment remains
controversial showing anti-tumor role and pro-tumor role. In sev-
eral murine transplantable tumor models, anti-cancer drugs (such
as oxaliplatin or anthracyclines) that induced immunogenic cell
death, triggered the local invasion of IL-17 producing γδ T cells,
which occurred before and was required for the subsequent inva-
sion of tumor-reactive CTL (50, 51). However, it was shown that
IL-17 producing γδ cells acts as tumor promoting cells by induc-
ing angiogenesis (52). In addition, Rei et al. demonstrated that
IL-17 producing Vγ6+ γδ cells promotes tumor growth in the ID8
ovarian cancer model and thus opposes the widely accepted anti-
tumor function of γδ cells (53). In addition to TCR dependent
pathways, NKG2D and DNAX accessory molecule-1 (DNAM-1)
expressed on Vγ9Vδ2 T cells plays a critical role in anti-tumor
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FIGURE 1 | Proposed mechanism of interaction between human γδT cell
and tumor cell. γδT cells activated through interaction of γδT cell receptor
with IPP produced via mevalonate pathway at higher concentration in tumor
cell. Besides that NKG2D provides activation signals upon binding to MICA/B
and ULBP of tumor antigens results in the release of cytokines and
chemokines such as IFN-γ, TNF-α, IL-2, IL-17, perforin, grazymes, CXCL-10, and
CXCL-13, which can directly lyse the tumor cell and can recruit other immune
cells like T cells (TH cells and TC cells), B cells, and dendritic cells (DC) to aid
killing of tumors. γδT cells expressing CD16 receptor (FCγRIII) interacts with
TAA mediate ADCC through activation of B cell.
response as shown in the Figure 1. NKG2D provides activation
signals upon binding to non-classical MHC molecules of the MHC
class-I chain-related molecules (MICA/B) and UL-16 binding pro-
tein (ULBP) families expressed on tumor cells (54). Nectin-like-5
expressed in carcinoma cells recognized by DNAX and provides
activation signals (50). γδ T cells also express CD16 (FCγRIII)
receptor, upon recognition of tumor associated antigens (TAA),
CD16/FCγRIII receptor binds to Fc portion of immunoglobu-
lin G (IgG) and leads to antibody-dependent cellular cytotoxicity
(ADCC) (55). In addition to the cytokines, cytotoxic soluble
factors, activated Vγ9Vδ2 T cells can produce large amount of
chemokines like CXCL-13 and CXCL-10 result in the recruitment
of B cells, macrophages, T cells, and NK cells toward the tumor
micro-environment (49). It leads to inhibition of tumor growth
and reduced survival of autologous tumor cells. γδ T cells have a
unique capacity to present antigens to both CD8 and CD4 T cells
and potentially elicit strong adaptive anti-tumor response.
Presently two strategies were applied for γδ T cell based can-
cer immunotherapy. One is the adoptive cell transfer of in vitro
expanded Vγ9Vδ2 T cells and second one is the administration of
pAg or aminobisphosphonates along with low-dose recombinant
IL-2 to stimulate Vγ9Vδ2 T cells in vivo. It has been shown that
the two synthetic molecule drugs bromohydrin pyrophosphate
(BrHPP) and zoledronate selectively activate human Vγ9Vδ2 T
cells in clinical trials. Bioactivity (EC50) of BrHPP (56, 57), and
zoledronate (58) were 24 nM and 1µM, respectively to activate
TCR Vγ9Vδ2 T cell clones and PB mononuclear cells in vitro.
Dieli et al. reported that increased survival rates in prostate cancer
patients when administered zoledronate (4 mg) in combination
with IL-2 (0.6× 106 IU) was observed (59). In another clinical
trial (60), administration of low-dose IL-2 (0.25 to 3× 106 IU)
in combination with pamidronate (90 mg) in multiple myeloma
patients showed that five out of nine patients had significant
in vivo activation and proliferation of Vγ9Vδ2 T cells, indicat-
ing that Vγ9Vδ2 T cells might contribute to this anti lymphoma
effect. Vγ9Vδ2 T cells from tumor infiltrate lymphocytes (TIL)
of colorectal cancer are able to eliminate cancer cells in vivo and
have been associated with reduced metastasis and longer mean
survival (61). BrHPP activated TCR Vγ9+ γδ T cells obtained
from healthy subjects co-incubated in vitro with B-lymphoma
cell targets coated with rituximab, enhance ADCC of target cells
(62). In primates, administration of pAg synthetic analogs and
low doses of IL-2 expand Vγ9Vδ2 T cells in lung tissue, which
in turn confer activity against human non-small cell lung cancer
(NSCLC) cell lines by increasing the secretion of IFN-γ, TNF-
α, and TRAIL (63). Phospho Ag-expanded Vδ2 T cells infusion
has also been tested in lymphoid neoplasms and renal cancer. In
metastatic renal carcinoma, six cycles of adaptive immunotherapy
with infusions of phospho Ag-expanded γδ T cells plus zoledronic
acid (4 mg) and low doses of IL-2 (1.4× 106 IU) caused complete
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remission without progression for 2 years (64). In vitro studies
reported γδ T cells killing efficacy was increased against three
cervical cancer cells pretreated with pamidronate and proved by
LDH cytotoxicity test (65). Elevated levels of Vγ9Vδ2 T cells in
the liver were found in hepatocellular carcinoma (HCC) patients
as well as tumor bearing mice compared to healthy controls,
indicating the importance of Vγ9Vδ2 T cell in the anti-tumor
immunity (66). Oberg et al. reported increased γδ T cell cytotox-
icity against pancreatic ductal adenocarcinomas (PDAC) in vitro
and in vivo in immunocompromised mice, when administered
healthy donors γδ T cell with Her2/Vγ9 bispecific antibodies (67).
Hence, novel regimens combining γδ T cells with drugs or mono-
clonal antibodies would be helpful for treatment of solid tumors
and hematological malignancies.
BURNS ANDWOUNDS
γδ T cells participate in several aspects of healing from burn
injuries and wounds. Healing is a dynamic and complex process
requiring constant communication between cells in the form of
cytokine release, cell-to-cell contacts, and cell-to-matrix interac-
tions. The epidermis is a barrier tissue that is exposed to the
environment and susceptible to injury. γδ T cells are found in
both epidermis and dermis of human skin express Vδ1 chain.
These skin-resident T cells involved in reepithelization of acute
and chronic wounds. Human epidermal αβ and Vδ1 bearing T
cells are able to produce insulin like growth factor upon activa-
tion and promote wound healing in a skin organ culture model
(68). Murine epidermal γδ T cells are named as DETCs because
of their unique dendritic morphology. DETC express an invariant
Vγ3Vδ1+ TCR. Oppeltz et al. reported that epidermal γδ T cells
play a major role in the expression of inducible nitric oxide syn-
thase (iNOS) at the burn wound site and is important in wound
closure and collagen deposition (69). Recently, it has been sug-
gested that DETC participate in tissue repair, likely through the
production of Th2 and Th17 cytokines (70), chemokines, and
growth factors. Hence the immediate goal of DETC is to repair
wound and maintain tissue integrity and homeostasis.
Wound occurs as a result of trauma, infection or by the patho-
logical infections. Cellular damage and stressed keratinocytes pro-
duce an unknown antigen, which binds with the TCR of DETC,
which are proximal to the wound (71). Further, DETC changes its
morphology and become rounded with in 4 h post wounding (72).
The rounded morphology of DETC correlates with functional
activity. The distal DETC to the wound retain dendritic and main-
tain tissue homeostasis. Activated DETC produce TNF-α, insulin
growth factor (IGF)-1, KGF-1, KGF-2, and up regulate the activa-
tion markers CD25 and CD69 in response to the epithelial damage
(73). Rapamycin, an immunosuppressor that is known to regulate
the DETC rounding by targeting the serine threonine kinase, cause
delay in cytokine production and wound healing (74). DETCs are
shown to produce lymphoid associated thymosin-β4 variant in
contact dermatitis that exhibits the anti-inflammatory role (75).
In normal condition, DETCs are slightly activated at the epider-
mal region by expressing the activation markers CD25, CD69, and
also secrete some cytokines in low amount that allows them for
quick activation in response to local trauma (76). DETC express
the co-stimulatory activating receptors like NKG2D, and H60c,
ligand expressed on wounded epidermis and shown to provide co-
stimulatory signals with NKG2D participating in TCR mediated
signaling (77). A prominent signaling by co-stimulatory mode of
DETC activation is by junctional adhesion molecule-like protein
(JAML) that is expressed by the DETC. The recognition of JAML to
its ligand coxsackie and adenovirus receptor (CAR) expressed by
the keratinocytes results in the recruitment of phosphoinositide
3-kinase (PI3K) (78) and also with the HLA4E10 (79) stimula-
tory antibody that helps in promoting wound healing as shown
in Figure 2. Recently, it was found that plexin B2 expressed on
keratinocytes and CD100 an intra cellular signaling domain of
DETCs shows much interaction and makes the cellular round-
ing via signals through ERK kinase and cofilin (80). Rani et al.
reported that, γδ T cells regulate myeloid cell activity, which in
turn enhances macrophage influx into the wound site to repair
wound (81).
γδ T cells also participate in the repair of epithelia in other
organs, such as intestine, lung, and cornea. γδ T cells play a key
role in the maintaining of intestinal mucosa by producing KGF.
Mice lackingγδT cells treated with a dextran sodium sulfate (DSS),
exhibit severe mucosal injury and decreased epithelial cell prolif-
eration (82). Mice deficient for TCR δ chain (TCRδ−/−) exhibit
significantly reduced inflammation and epithelial repair in the
lung after bleomycin treatment (83) and also in the corneal epithe-
lial abrasion (84). In the lung injury, γδ T cells are required for the
neutrophils influx and also produce IL-17, which are responsible
for the inflammatory response and epithelial repair (85). Corneal
healing involves both epithelium and sensory nerves that have a
trophic effect for the epithelium. Intracellular cell adhesion mole-
cule (ICAM)-1 and CCL20 chemokine are necessary for attracting
theγδT cells into the healing epithelium (86).γδT cells are respon-
sible for the secretion of cytokines such as IL-17, IL-22, and the
influx of neutrophils and platelets, which contribute to the epithe-
lium healing. Accumulation of neutrophils and platelets leads to
the rise in vascular endothelial growth factor (VEGF), which is
required for nerve regeneration (87).
AUTOIMMUNE DISEASES
Autoimmune diseases are characterized by abnormal immune
responses to self antigens. These diseases are induced by many
environmental factors on a genetically susceptible background,
which lead to production of huge number of inflammatory
cytokines and auto-antibodies to make path for the outbreak and
progression of the disease. The roles of γδ T cells in autoimmune
diseases are not yet very clear. Bendersky et al. showed that ele-
vated number of Vγ9Vδ2 T cells (~35%) in synovial fluid and PB,
produced TNF-α and IFN-γ during the pathogenesis of juvenile
idiopathic arthritis (JIA). Further, activation of γδ T cells leads
to apoptosis of synovial fibroblasts, the effect of which is mani-
fested in JIA (88). γδ T cells in intestine were significantly reduced
during intestinal inflammation, which leads to the uncontrolled
activity of CD4+ T helper cells to cause autoimmune inflam-
matory bowel disease called Crohn’s disease (89). The role of
γδ T cells in allergic encephalomyelitis and multiple sclerosis is
ambiguous. γδ T cells were certainly abundant in cerebrospinal
fluid of the respective mouse models but their precise role is not
yet established (90). In non-obese diabetic mouse model, γδ T
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FIGURE 2 | Mechanism of action of murine skin resident γδT cells
in wound repair. During keratinocyte damage, the epidermal γδT cells
(DETCs) are activated upon recognition of an unknown antigen, rounding of
the DETCs occur and produce thymosin β4 and cytokines like TNF-α, IFN-γ,
and IL-2 required for anti-inflammatory response and wound healing.
Engagement of NKG2DR with H60c and JAML–CAR interactions also
enhances the production of these cytokines and provide epidermal repair.
(JAML, junction adhesion molecule like protein; CAR, coxsackie and
adenovirus receptor; TNF, tumor necrosis factor; IFN, interferon; IL,
interleukin; NKG2DR, natural killer cell activating receptor).
cells infiltrate into islet cells and secrete IL-17 to cause apop-
tosis. Antibody mediated blockade of IL-17 stopped the process
and rescued mouse from diabetes (91). γδ T cells cross react with
aminoacyl-tRNA synthetases of the muscle cells that lead to the
pathogenesis of myositis, an inflammation of muscle tissues caused
by autoimmune T cells (92).
Behcet’s disease is an immune mediated disorder that is often
associated with the symptoms like ulceration of mucous mem-
brane, skin, and ocular problems. In general, normal individuals
consist of CD45RA− CD45RO+ Vγ9+Vδ2+ T cells but as the
disease progress abnormal γδ T cells with CD45RA+ CD45RO−
Vγ9+Vδ2+ phenotype are increased in number and activated, then
produced IL-2R in patients suffering with Behcet’s disease (88).
Infliximab, is a chimeric monoclonal antibody against TNF-α, sup-
press the Vγ9Vδ2 T cell expansion and activation by blocking the
TNF receptor on Vγ9Vδ2 T cells. Moreover, it also reduces the
cell-mediated immune responses by reducing the expression TNF
RII, perforin, granzyme-A, and IFN-γ production from Vγ9Vδ2
T cell (93).
Psoriasis is speculated as the T cell operated chronic inflam-
matory skin disease (94), but the mechanisms of pathogenesis
are still poorly understood. Chemokine receptor CCR6 (recep-
tor for a CCL20) is very abundant in psoriatic skin T cells.
Chemokine receptors are transmembrane proteins that are acti-
vated by chemokines, which play key roles in cell trafficking, cell
motility, and survival. CCR6 regulates epidermal trafficking of γδ
T cell subsets in the skin (95). The chemokine receptor CCR6 is
expressed on the Th17 cells andγδT cells, which produce cytokines
like IL-17 and IL-22, TNF-α, and IL-20 (94). IL-22 plays a key role
in the activation of immunity and has been implicated in the
pathogenesis of psoriasis (96). γδ T cells from CCR6 KO mice
not only failed to accumulate in the epidermis after IL-23 treat-
ment and even though entered into the epidermis produced low
amounts of IL-22 compared with wild type γδ T cells. Hence, this
data suggest that not only recruitment but also function of γδ T
cells may be impaired in the absence of CCR6 (97). Laggner et al.
showed that, redistribution of Vγ9Vδ2 T cells from PB to skin in
psoriasis patients as compared to the healthy control. These skin
homing Vγ9Vδ2 T cells produce the psoriasis relevant cytokines
IFN-γ, TNF-α, and IL-17A similar to blood derived Vγ9Vδ2 T
cells (98, 99). Prominent roles for skin homing Vγ9Vδ2 T cells
are influencing the resident immune and epithelial cells by the
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Table 1 | Antigen recognition and functions of γδT cells in various diseases. γδT cells recognizes various antigenic factors and produce respective
chemokines and cytokines to protect immune system against from different diseases like pathogenic infections, cancer, wound repair, and autoimmune.
S. No. Disease Stimulator/activator for γδT cells Function of γδT cells in immune-protection
1. Pathogenic infections
a. Tuberculosis
(M. tuberculosis)
HMBPP produced by the 2-C-methyl-D-erythritol
4-phosphate (MEP) pathway in microorganisms
Produce IL-22, IL-17, and IFN-γ. Regulating both innate and
adaptive immunity
b. Malaria
(P. falciparum)
Schizont associated antigen (SAA) and HMBPP IL-10, IL2, IL-1β, and IFN-γ degranulation of infected RBC and
merozoites
c. AIDS (HIV ) Recognize the envelope protein GP 120 by CCR5
receptor on Vγ9Vδ2 T cells
Activates P38 MAP kinase, which promotes the FAS
dependent caspase activation and induces the cell death
2. Cancer Vγ9Vδ2 TCR recognizes endogenous IPP, produced
by mevalonate pathway in tumor cells
Increased secretion of perforin/granzymes, TNF-α, IFN-γ, and
suppress the tumor
NKG2D expressed on γδT cells recognizes MICA/B
and ULBP families expressed on tumor cells
Produce IFN-γ, IL-17, and chemokines, which recruit the
macrophages, NK cells, B cells, and T cells
3. Wound repair Non-specific antigen recognition by DETC IL-2, TNF-α, IFN-γ, KGF-1, and KGF-2 are produced against
the damaged keratinocytes result in the healing of wound
4. Autoimmune diseases Recognizes self antigens by γδTCR Enhances the production of IL-17, IL-23, and IFN-γ. The exact
mechanism of γδT cells in these diseases is not yet clear
HMBPP, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate; γδTCR, γδT cell receptor; IFN, interferon; IL, interleukin; GP 120, glycoprotein; CCR, chemokine receptor;
MAP, mitogen activated protein; NKG2D, natural killer cell activating receptor; MICA/B, MHC class-I chain-related molecule; ULBP, UL-16 binding protein; TNF, tumor
necrosis factor; DETC, dendritic epidermal γδT cell; KGF, keratinocyte growth factor.
rapid release of pro-inflammatory cytokines, the recruitment of
immune cells from the circulation, and in tissue remodeling by
the release of growth factors (99), which make Vγ9Vδ2 T cells as
the biomarker of psoriasis.
γδ T cells show enhanced antigen-presenting cell (APC) func-
tions, which may play a role in the pathogenesis of RA by over
activating T and B cells. Abnormal activation of Th1 and Th17
cells result in the production of pro-inflammatory cytokines,
which play crucial role in the pathogenesis of RA (100). Peripheral
Vγ9Vδ2 T cells after stimulation with IPP in vitro are shown to
upregulate the expression of APC specific molecules HLA-DR and
CD80/86 and presented soluble antigens and synthetic peptides to
CD4+ T cells and B cells thus contributing to activation of CD4+
T cells and being associated with RA onset and disease progres-
sion (100). A subset of CD27+ CD25high Vδ1 T cells expressing
FoxP3 were gradually decreased in the PB of systemic lupus ery-
thematosus patients progressing in the pathogenesis of SLE and
these regulatory γδ T cells could be generated in vitro when stim-
ulated with anti γδ-TCR in presence of IL-2 and transforming
growth factor-beta (TGF-β) (101). The activating marker CD69
and HLA-DR were up regulated while the expression levels of the
inhibiting receptor CD94/NKG2A remained low after the antigen
stimulation on these γδ T cells, upon activation might lead to the
over activation of γδ T cells in patients with SLE (102).
Graft rejection is a serious problem during transplanting of
solid organs. Conventionally, the B cells and αβ T cells of adaptive
immune system were considered to be the key in this phenomenon
as they have immune memory and can bind numerous antigens.
However, there is an evidence that γδ T cells play a vital role in
graft rejection. Gorczynski et al. studied the role of γδ T cells in
skin graft rejection using mouse model (103). γδ T cells were not
restricted by immunosuppressive drugs during organ transplan-
tation. Some subsets of γδ T cells expand oligo clonally and the
reasons for this expansion are unknown but may be linked to per-
sistent viral infections. It has been suggested that quantification
of γδ T cells in PB may not be essential to decide graft tolerance
(104). The known role of γδ T cells in autoimmune diseases is
limited, so an extensive research has to be focused particularly
on the effects of these cells in the pathogenesis and development
of disease and ultimately for the development of γδ T cell based
therapies.
γδ T cells functions in various diseases, described in the review
are summarized in the Table 1.
IMMUNOTHERAPY
Immunotherapy has become an increasingly attractive option for
the treatment of cancer (105). γδ T cells may be an excellent target
for modulation of immune responses in human diseases. Enhanc-
ing γδ T cell functions may open the possibility to formulate new
immunotherapeutic regimens, which could impact the improve-
ment of immune control of various diseases. Aminobisphospho-
nates like zoledronate, pamidronate, and BrHPP were well-studied
among the numerous activators of Vγ9Vδ2 T cells. IPP is an inter-
mediate metabolite of mevalonate pathway. Bisphosphonates may
activate Vγ9Vδ2 T cells, by inhibiting the key enzyme farnesyl
pyrophosphate synthase of mevalonate pathway in certain tumors
leads to upregulating the endogenous pool of IPP. Mevalonate
is the product of HMG-CoA reductase, a rate limiting enzyme
subject to tight regulation. However, high exogenous mevalonate
concentration would bypass normal regulation and indirectly
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stimulates Vγ9Vδ2 T cells by increasing endogenous IPP levels
(106). Taken together, bisphosphonates and mevalonate may acti-
vate Vγ9Vδ2 T cells and aid in curing bacterial infections (107).
Bisphosphonates were proven to treat gliomas (108). A clinical trial
of immunotherapy using a combination of zoledronate, a bisphos-
phonate,and IL-2 was found to alleviate renal cell carcinoma (109).
HMBPP is one of the key ligands that activate Vγ9Vδ2 T cells.
HMBPP is produced by the 2-C-methyl-d-erythritol 4-phosphate
(MEP) biosynthetic pathway in microorganisms. HMBPP is nearly
1000-fold more effective than IPP for the in vitro activation of
Vγ9Vδ2 T cells. Vγ9Vδ2 T cells express surface marker CCR5,
which is recognized by gp120 of HIV. This leads to apoptosis of
HIV infected cells through a caspase mediated pathway. It has
been suggested that by triggering rapid proliferation of Vγ9Vδ2
T cells may help in curing HIV infection (110). γδ T cell based
immunotherapy might have a beneficial effect in patients with
chronic hepatitis C virus infection (111).
αβT cell populations potently attack specific targets but are lim-
ited by their specificity, where as γδ T cells in combination with
tumor-targeting antibodies might provide anti-tumor cytotoxic
effects and also long-lasting protection upon antigen presenta-
tion. γδT cells have dual role of stimulating both γδT cell-directed
anti-tumor activity and antigen-specific CD4 and CD8 αβ T cell
responses. γδ T cells are attractive agents for cancer immunother-
apy because they are not MHC restricted like conventional T
cells. So, a single vaccine can be used in all individuals regard-
less of MHC haplotype (112). Memory like expansion of Vγ9Vδ2
T cells has been reported in primates after subclinical systemic
infection and reinfection with attenuated Listeria monocytogenes
strains (20). γδ T cells acquire memory in order to play protective
antiviral and anti-tumor roles. The direct or indirect stimulation
of γδ T cells by TLR agonists could be a strategy to optimize Th1
mediated immune responses as adjuvant in clinical trial of cancer
immunotherapy (113). Recent studies suggest that, combination
of γδ T cells with therapeutic monoclonal antibodies can effi-
ciently mediate ADCC against tumors (114). Chronic wounds are
an increasing clinical problem, understanding advanced mecha-
nisms of DETC during wounds and burns in humans suggesting
possible therapeutic targets for tissue repair and skin homeosta-
sis. Disabling γδ T cells at the specific site by using monoclonal
antibodies is a viable therapeutic option for the treatment of
autoimmune diseases. Peters et al. reported immunosuppression
of γδ T cells by using anti-CD28 mAb and antagonized by TLR-2
ligands (113). Suppressive γδ T cells could have major therapeutic
potential for the control of autoimmunity or allergic reactions.
Enhancing the activity of Tregs, which inturn secrete PD-1 and
CTLA-4 to suppress the activity of γδ T cells, could improve treat-
ment for the autoimmune diseases (115). Modulation of these
immunosuppressive check points may be interesting clinical trial
in the γδ T cells based immunotherapy.
CONCLUDING REMARKS AND FUTURE DIRECTIONS
The role of γδ T cells in immunotherapy has gained specific
importance due to their prominent function involving directly
or indirectly in the rehabilitation of the diseases. γδ T cells act as
connecting bridge between both the innate and adaptive immune
responses without the antigen presentation and producing some
important key cytokines like IFN-γ and TNF-α. When stimulated
with the combination of aminobisphosphonates and IL-2 acti-
vate the Vγ9Vδ2 T cells further and they can also act as the APCs
to treat particular infections and tumors. Factors that potenti-
ate the pathogenesis of γδ T cells in autoimmune diseases are yet
to be revealed so as to develop drugs, which can target the γδ
T cell in particular. New strategies and models that target the
molecules involved during disease onset and progression need
to be developed, as this makes a pavement for γδ T cell based
immunotherapy. New ligands and chemokines responsible for
activation and effector functions of γδ T cells are to be deciphered.
Many new molecules and proteins can be designed to trigger the
γδ T cell through a TCR independent pathway. Vaccines have to
be developed to enhance the production levels of chemokines and
cytokines by these γδ T cells at the tumor site. For the preparation
of large number of cells for adoptive cell transfer, it is necessary
to develop better antigens, which stimulate γδ T cell expansion
in vitro. Further, clinical trials are required for the γδT cell targeted
immunotherapy in case of chronic infections and diseases. Further
research might shed more light on the in depth understanding of
the underlying mechanisms of the antigen recognition and key
factors influencing the γδ T cell production during the disease.
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